|
Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies |
Mar 2024 |
Expert Opinion on Biological Therapy |
Myelodysplastic Syndromes (MDS) |
|
Oral therapy for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a revolution in progress |
Jul 2023 |
Expert Review of Anticancer Therapies |
Myelodysplastic Syndromes (MDS) |
|
Myelodysplastic Syndromes: A Review of Therapeutic Progress Over the Past 10 Years |
Jun 2020 |
Expert Review of Anticancer Therapy |
Myelodysplastic Syndromes (MDS) |
|
Getting personal with myelodysplastic syndromes: is now the right time? |
Apr 2019 |
Expert Review of Hematology |
Myelodysplastic Syndromes (MDS) |
|
Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter? |
Mar 2020 |
Expert Review of Hematology |
Myelodysplastic Syndromes (MDS) |
|
Management of aplastic anemia after failure of frontline immunosuppression |
Jul 2019 |
Expert Review of Hematology |
Aplastic Anemia |
|
Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole? |
Sep 2020 |
Expert Review of Hematology |
Myelodysplastic Syndromes (MDS) |
|
Novel therapeutic choices in immune aplastic anemia |
Sep 2020 |
F1000Research |
Aplastic Anemia |
|
The role of androgen therapy in acquired aplastic anemia and other bone marrow failure syndromes |
May 2023 |
Frontiers in Oncology |
Aplastic Anemia |
|
Targeting the Microenvironment in MDS: The Final Frontier |
Jul 2020 |
Frontiers in Pharmacology |
Myelodysplastic Syndromes (MDS) |
